The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s disease with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija. The European Medicines Agency starts all he procedures in Europe.
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations. – We are leading the inclusion internationally of a trial with sublingual Apomorphine. Our Unit leads the inclusion of randomized patients comparing sublingual apomorphine versus the classic subcutaneous apomorphine for the indication in blocking off.
Our Unit has achieved to be activated in this outstanding project and so serious pathology. We will participate in its development and also in a phase III.
We appreciate the great effort made by our patients to contribute to the development of this protocol that aims to verify the safety of a truly innovative drug.
We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.
We have reached the first position, in December 2019, in the international inclusion of patients in the trial with sublingual apomorphine and motor blocks in Parkinson. We are also leading the national inclusion of patients in the Clarity AD trial (monoclonal anti-amyloid antibody in early Alzheimer) Finally, in the Graduate trial (monoclonal subcutaneous in Alzheimer)…
The UDIC has been selected to initiate a line of several clinical trials with this D1 dopamine agonist, with a similar mechanism of action to Apomorphine. It will be evaluated in initial Parkinson’s and also in advanced Parkinson’s disease, as add on levodopa therapy. An open label extension is planned.
Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.
The UDIC will start a new clinical trial that evaluates the subcutaneous administration of levodopa, using a continuous perfusion pump, to treat motor fluctuations in advanced Parkinson’s isease. It will compare with standard Levodopa in a double-blind study. Up to now this has not been possible due to high volume required. This “ultra concentrated” levodopa…